GlobeNewswire

Hennick Humber Hospital Opened Its Doors to 150 Students to Explore the Future of Healthcare
04/11/2026
Annual Take Our Kids to Work Day experience gave young people a firsthand look at the people, technology and career possibilities shaping modern healthcare TORONTO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- What did the future [...]
Pacific Health Care Organization, Inc. Reports its Third Quarter 2026 Financial Results
04/11/2026
Irvine, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) filed yesterday with the Securities and Exchange Commission (the “SEC”) its quarterly report on Form 10-Q [...]
Neion Bio Taps John Maga as Head of Biologics and CMC to Expand Capabilities In Innovative Development
04/11/2026
Veteran biopharmaceutical executive brings deep experience across complex therapeutic modalities as Neion expands the Raptor platform for innovative and difficult-to-express proteins NEW YORK, Nov. 04, 2026 (GLOBE [...]
Standard Dental Labs Acquires M&D Dental Arts; Announces December 1 Launch Target for Bridge AI Software
04/11/2026
Acquisition expected to double Orlando laboratory output; internally developed platform connects digital dentistry workflows and lays groundwork for AI-assisted restoration design ORLANDO, Fla., Nov. 04, 2026 (GLOBE [...]
Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026
04/11/2026
Lyon (France), November 4, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its nine-month 2026 financial results on Tuesday, November 24, 2026. The [...]
Valneva publiera ses résultats financiers consolidés des neuf premiers mois de l’année le 24 novembre 2026
04/11/2026
Lyon (France), le 4 novembre 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui qu’elle publiera ses résultats financiers des neuf premiers mois de l’année [...]
Virbac : Declaration of the number of shares and voting rights 10/2026
04/11/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 10/2026
04/11/2026
DÉCLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Tessera Therapeutics to Present New Preclinical Data Supporting its In Vivo Sickle Cell Disease Program and In Vivo CAR-T Applications at the 68th American Society of Hematology Annual Meeting
04/11/2026
SOMERVILLE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tessera Therapeutics, Inc. (“Tessera”), a clinical-stage biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced [...]
Zelluna ASA awarded NOK 15.6 million Research Council of Norway grant to further advance TCR-NK manufacturing
04/11/2026
Oslo, 4 November 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the [...]
Asgard Therapeutics announces publication in Immunity demonstrating induction of cancer-fighting tertiary lymphoid structures across seven tumor types – and will present new AT-108 biomarker data at SITC 2026
04/11/2026
Study in Immunity highlights Asgard's ability to generate potent immunogenic tertiary lymphoid structures (imgTLSs) solely by reprogramming tumor cells into antigen-presenting conventional type 1 dendritic cells (cDC1s [...]
Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
04/11/2026
First interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AML HOUSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“ [...]
Ichnos Glenmark Innovation (IGI) to Present Updated Clinical Data for ISB 2001 (ABBV-2001) in Relapsed/Refractory Multiple Myeloma at 68th ASH Annual Meeting
04/11/2026
ISB 2001 (ABBV-2001) is an investigational first- and only-in-class CD38 × BCMA × CD3 trispecific T-cell engager Updated data from the Phase 1 TRIgnite-1 study include longer follow-up from the dose-escalation phase and [...]
Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
04/11/2026
First clinical data for dapolsertib monotherapy: initial results from the Phase II JASPIS-01 study of dapolsertib (MEN1703), a first-in-class oral dual PIM/FLT3 kinase inhibitor, in patients with relapsed/refractory (r/ [...]
J-Star Holding Co., Ltd. Provides Update on Capital Structure Authorization and Strategic Execution Timeline
04/11/2026
TAICHUNG, Taiwan, Nov. 04, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), an innovator in advanced composite manufacturing, today provided a clarification regarding the [...]
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Hematological Malignancies at ASH 2026
04/11/2026
Three iadademstat abstracts have been accepted for presentation Updated data from the ongoing Phase Ib ALICE-2 trial combining iadademstat with azacitidine and venetoclax in newly diagnosed, unfit AML patients showed a [...]
Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
04/11/2026
Pelareorep-driven changes in the tumor microenvironment are associated with tumor responses and shrinkage Immune activation levels more than doubled in nearly all patients after one cycle of treatment Substantial [...]
Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual Meeting
04/11/2026
MGX-001 data establish preclinical proof-of-concept in hemophilia A On track to initiate global clinical trial in 2027 EMERYVILLE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) ( [...]
Applied Biologics Announces Full Enrollment of BIOxHEAL™ Phase 3 Sentinel Safety Cohort
04/11/2026
Completion of sentinel cohort enrollment triggers independent Data and Safety Monitoring Board review, a required milestone before initiation of the 243-patient randomized controlled phase SCOTTSDALE, Ariz., Nov. 04, [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum